HomeCompareNILE vs ABBV

NILE vs ABBV: Dividend Comparison 2026

NILE yields 1632.65% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NILE wins by $1522521578.55M in total portfolio value
10 years
NILE
NILE
● Live price
1632.65%
Share price
$0.12
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1522521578.65M
Annual income
$1,358,802,192,094,537.50
Full NILE calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — NILE vs ABBV

📍 NILE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNILEABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NILE + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NILE pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NILE
Annual income on $10K today (after 15% tax)
$138,775.51/yr
After 10yr DRIP, annual income (after tax)
$1,154,981,863,280,356.80/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, NILE beats the other by $1,154,981,863,259,300.80/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NILE + ABBV for your $10,000?

NILE: 50%ABBV: 50%
100% ABBV50/50100% NILE
Portfolio after 10yr
$761260789.38M
Annual income
$679,401,096,059,654.60/yr
Blended yield
89.25%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

NILE
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NILE buys
0
ABBV buys
0
No recent congressional trades found for NILE or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNILEABBV
Forward yield1632.65%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$1522521578.65M$102.3K
Annual income after 10y$1,358,802,192,094,537.50$24,771.77
Total dividends collected$1510699531.51M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: NILE vs ABBV ($10,000, DRIP)

YearNILE PortfolioNILE Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$173,965$163,265.31$11,550$430.00+$162.4KNILE
2$2,840,582$2,654,439.16$13,472$627.96+$2.83MNILE
3$43,546,759$40,507,336.46$15,906$926.08+$43.53MNILE
4$626,956,291$580,361,258.90$19,071$1,382.55+$626.94MNILE
5$8,479,854,706$7,809,011,473.99$23,302$2,095.81+$8479.83MNILE
6$107,783,962,236$98,710,517,700.67$29,150$3,237.93+$107783.93MNILE
7$1,287,916,677,762$1,172,587,838,170.00$37,536$5,121.41+$1287916.64MNILE
8$14,472,761,108,802$13,094,690,263,596.54$50,079$8,338.38+$14472761.06MNILE
9$153,008,772,484,665$137,522,918,098,247.10$69,753$14,065.80+$153008772.41MNILE
10$1,522,521,578,653,130$1,358,802,192,094,537.50$102,337$24,771.77+$1522521578.55MNILE

NILE vs ABBV: Complete Analysis 2026

NILEStock

BitNile Holdings, Inc., through its subsidiaries, designs, develops, manufactures, and sells power system solutions for the defense/aerospace, industrial, automotive, telecommunications, healthcare, medical/biopharmaceutical, and textile industries in North America, Europe, the Middle East, and internationally. It offers switching and uninterruptible power supplies, power conversion and distribution equipment frequency converters, and transformer and power rectifiers; radio frequency and microwave filters, diplexers, multiplexers, detectors, switch filters, integrated assemblies, and detector logarithmic video amplifiers; and custom computer-based automated test equipment, turnkey systems, high precision calibration equipment, advance power systems, and project management and engineering solutions. The company also provides power conversion and display solutions; residential and commercial high-speed EV charging solutions; commercial loans, convertible notes, and revolving lines of credit; and virtual training courses through the LightSpeedVT platform, as well as creates various media, communications, and content, including web development, corporate communications, social media, and scripted and unscripted television. In addition, it invests in public and private companies; and various commercial and residential real estate, including hospitality, multifamily, and industrial properties, as well as operates hotels and data centers. Further, the company engages in Bitcoin mining and other activities, as well as provides digital marketing services. It sells its products directly through its sales force, as well as through independent manufacturer representatives and distributors. The company was formerly known as Ault Global Holdings Inc. and changed its name to BitNile Holdings, Inc. in December 13, 2021. BitNile Holdings Inc. was incorporated in 1969 and is headquartered in Las Vegas, Nevada.

Full NILE Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this NILE vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NILE vs SCHDNILE vs JEPINILE vs ONILE vs KONILE vs MAINNILE vs JNJNILE vs MRKNILE vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.